Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04287049 · ClinicalTrials.gov registry record · Phase 2
A Study of Standard Drugs for Mycobacterium Avium Complex
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04287049: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT04287049 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04287049, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.
Interventions
- DRUG Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2025-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04287049
The ClinicalTrials.gov registry entry for NCT04287049 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azithromycin is the first listed.
NCT04287049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04287049 about?
NCT04287049 is a clinical study titled "A Study of Standard Drugs for Mycobacterium Avium Complex". To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.
What is the current status of trial NCT04287049?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2020-02-24. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT04287049?
The interventions under investigation include: Azithromycin (DRUG).
Who is sponsoring clinical trial NCT04287049?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.